ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer

15 Jul 2022

Recognition of commendable, longstanding dedication to the field of cancer immunotherapy

Oegstgeest, 15 July 2022 – ISA is delighted to announce that our Chief Scientific Officer (CSO) and Founder, Professor Dr. Cornelis “Kees” Melief has been nominated and selected by the Board of Directors of the Society for Immunotherapy of Cancer (SITC) as a Fellow of the Academy of Immuno-Oncology (FAIO) . The fellowship recognises Prof. Melief’s inspiring contributions and dedication to cancer immunotherapy, and will be presented at the SITC’s 37th Annual Meeting in Boston, 8-12 November 2022.

SITC is a professional society of scientists, clinicians, government representatives, and industry leaders

Read more »